Malaria: Difference between revisions
From WikiDemocracy
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| Line 159: | Line 159: | ||
[https://www.nature.com/articles/nature.2012.11785 by Declan Butler 9/11/12 nature] | [https://www.nature.com/articles/nature.2012.11785 by Declan Butler 9/11/12 nature] | ||
Interim poor results of RTS,S vaccine trial in African children raise question marks over deployment. | Interim poor results of RTS,S vaccine trial in African children raise question marks over deployment. | ||
=====Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial===== | |||
[https://www.sciencedirect.com/science/article/pii/S0140673623025114 by Mehreen S Datoo DPhil 16/2/24 ScienceDirect] | |||
Recently, we found that a new malaria vaccine, R21/Matrix-M, had over 75% efficacy against clinical malaria with seasonal administration in a phase 2b trial in Burkina Faso. Here, we report on safety and efficacy of the vaccine in a phase 3 trial enrolling over 4800 children across four countries followed for up to 18 months at seasonal sites and 12 months at standard sites. | |||
